Switch theme
Sign up to access all valuation multiples
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
1996
287
LTM Revenue $231M
LTM EBITDA $4.2M
$13.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
PetMeds has a last 12-month revenue of $231M and a last 12-month EBITDA of $4.2M.
In the most recent fiscal year, PetMeds achieved revenue of $281M and an EBITDA of -$1.1M.
PetMeds expects next 12-month revenue of XXX and NTM EBITDA of XXX
See PetMeds valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $257M | $281M | XXX | XXX | XXX |
| Gross Profit | $78.1M | $71.0M | XXX | XXX | XXX |
| Gross Margin | 30% | 25% | XXX | XXX | XXX |
| EBITDA | $2.1M | -$1.1M | XXX | XXX | XXX |
| EBITDA Margin | 1% | 0% | XXX | XXX | XXX |
| Net Profit | $21.1M | $0.2M | XXX | XXX | XXX |
| Net Margin | 8% | 0% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, PetMeds's stock price is $3.
PetMeds has current market cap of $62.4M, and EV of $13.4M.
See PetMeds trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13.4M | $62.4M | XXX | XXX | XXX | XXX | $0.19 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, PetMeds has market cap of $62.4M and EV of $13.4M.
PetMeds's trades at 0.1x LTM EV/Revenue multiple, and 3.2x LTM EBITDA.
Analysts estimate PetMeds's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for PetMeds and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $13.4M | XXX | XXX | XXX |
| EV/Revenue | 0.1x | XXX | XXX | XXX |
| EV/EBITDA | 4.8x | XXX | XXX | XXX |
| P/E | 44.9x | XXX | XXX | XXX |
| P/E/Growth | -1.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPetMeds's NTM/LTM revenue growth is -2%
PetMeds's revenue per employee for the last fiscal year averaged $1.0M, while opex per employee averaged $0.3M for the same period.
Over next 12 months, PetMeds's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate PetMeds's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for PetMeds and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 1% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -152% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -1% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.0M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 9% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 20% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 31% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Mad Paws | XXX | XXX | XXX | XXX | XXX | XXX |
| i-Tail | XXX | XXX | XXX | XXX | XXX | XXX |
| Central Garden & Pet | XXX | XXX | XXX | XXX | XXX | XXX |
| Dogness | XXX | XXX | XXX | XXX | XXX | XXX |
| Freshpet | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PetMeds acquired XXX companies to date.
Last acquisition by PetMeds was XXXXXXXX, XXXXX XXXXX XXXXXX . PetMeds acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was PetMeds founded? | PetMeds was founded in 1996. |
| Where is PetMeds headquartered? | PetMeds is headquartered in United States of America. |
| How many employees does PetMeds have? | As of today, PetMeds has 287 employees. |
| Who is the CEO of PetMeds? | PetMeds's CEO is Ms. Sandra Y. Campos. |
| Is PetMeds publicy listed? | Yes, PetMeds is a public company listed on NAS. |
| What is the stock symbol of PetMeds? | PetMeds trades under PETS ticker. |
| When did PetMeds go public? | PetMeds went public in 1997. |
| Who are competitors of PetMeds? | Similar companies to PetMeds include e.g. Mad Paws, i-Tail, Central Garden & Pet, Dogness. |
| What is the current market cap of PetMeds? | PetMeds's current market cap is $62.4M |
| What is the current revenue of PetMeds? | PetMeds's last 12-month revenue is $231M. |
| What is the current EBITDA of PetMeds? | PetMeds's last 12-month EBITDA is $4.2M. |
| What is the current EV/Revenue multiple of PetMeds? | Current revenue multiple of PetMeds is 0.1x. |
| What is the current EV/EBITDA multiple of PetMeds? | Current EBITDA multiple of PetMeds is 3.2x. |
| What is the current revenue growth of PetMeds? | PetMeds revenue growth between 2023 and 2024 was 9%. |
| Is PetMeds profitable? | Yes, PetMeds is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
